GCP
TRIB

GSA Capital Partners’s Trinity Biotech TRIB Stock Holding History

GSA Capital Partners’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,918
Closed -$170K – 1996
2016
Q4 		$170K Buy
+4,918
New +$169K 0.01% 1623
2016
Q2 		– Sell
-2,938
Closed -$171K – 1918
2016
Q1 		$171K Buy
2,938
+195
+7% +$10.3K 0.01% 1523
2015
Q4 		$161K Buy
+2,743
New +$162K 0.01% 1681
2015
Q1 		– Sell
-3,424
Closed -$300K – 2209
2014
Q4 		$300K Buy
+3,424
New +$295K 0.02% 1259
2014
Q3 		– Sell
-4,240
Closed -$488K – 1934
2014
Q2 		$488K Buy
4,240
+1,640
+63% +$194K 0.02% 1156
2014
Q1 		$315K Buy
2,600
+1,000
+63% +$131K 0.02% 1089
2013
Q4 		$201K Buy
+1,600
New +$192K 0.02% 1466
2013
Q3 		– Sell
-2,900
Closed -$244K – 1667
2013
Q2 		$244K Buy
+2,900
New +$241K 0.03% 982

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

GSA Capital Partners's TRIB Position: Q1 2017 in Review

GSA Capital Partners sold out of Trinity Biotech (TRIB) in Q1 2017, closing a stake of 4,918 shares — an estimated $170K sold.

GSA Capital Partners first reported a position in TRIB in Q2 2013 and held it in 8 quarters. The position peaked at $488K in Q2 2014. 67 funds tracked by Wall St. Rank hold TRIB as of Q1 2017.

  • GSA Capital Partners reported no remaining Trinity Biotech position as of Q1 2017 after selling out during the quarter.
  • GSA Capital Partners sold 4,918 Trinity Biotech shares in Q1 2017, an estimated $170K.
  • GSA Capital Partners first reported a position in Trinity Biotech in Q2 2013 and held it in 8 quarters.
  • GSA Capital Partners's Trinity Biotech position peaked at $488K in Q2 2014.
  • 67 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2017.

Based on GSA Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.